The emergence of medications such as Ozempic, Wegovy, and Mounjaro has garnered significant attention due to their potential for substantial weight loss. As usage has soared, concerns regarding unexpected cosmetic side effects, including hair thinning, have intensified. A recently published study highlights a modest, measurable rise in the risk of hair loss among users of GLP-1 receptor agonists, prompting discussions about the implications for patients. Despite these findings, experts urge not to cease treatment without professional guidance.

Study Findings on Hair Loss Risk

The research, featured in The BMJ, involved an analysis of electronic health records of adults diagnosed with type 2 diabetes. It compared individuals taking GLP-1-based drugs versus those on alternative diabetes treatments. Results indicated that patients on GLP-1 medications faced a 37 per cent higher risk of developing non-scarring hair loss compared to individuals using SGLT-2 inhibitors, and a 68 per cent higher risk compared to those using DPP-4 inhibitors.

Despite these figures, the overall risk remains relatively low, estimated at approximately three to nine instances of hair loss per 1,000 patients annually. This information arises amid rising popularity in India for GLP-1 medications, which mimic gut hormones, manage appetite, and slow digestion. Originally prescribed for type 2 diabetes, their use for obesity management continues to expand, spurred by increased awareness and social media visibility.

Recent developments include the approval of Wegovy, a higher dose of semaglutide, for treating severe fatty liver disease by the Central Drugs Standard Control Organisation (CDSCO) in India, indicating the broadened applications of these drugs in the medical field.

Temporary Nature of Hair Loss and Contributing Factors

The study establishes a correlation rather than a direct causative link between these medications and hair loss. Most reported cases involve non-scarring alopecia, where hair follicles are intact, allowing for potential regrowth. Experts suggest this aligns with established understandings of rapid weight loss that can lead to temporary shedding, known as telogen effluvium.

Dr. Aparna Santhanam from PD Hinduja Hospital in Mumbai noted that while there might be a slight increase in temporary hair loss with GLP-1 drugs, the overall risk is minimal. Dr. Mayank Singh, a hair transplant surgeon, emphasised that factors like rapid weight loss, lower caloric intake, and deficiencies in nutrients could play significant roles in hair shedding, rather than the medications themselves.

Telogen effluvium occurs when a significant change in weight triggers more hair follicles to enter the shedding phase. This typically becomes visible two to four months post-weight loss, influenced by calorie deficits, nutritional inadequacies, and the physical stresses associated with quick weight changes.

Recommendations and Outlook for Patients

Dermatologists confirm that telogen effluvium is usually self-limiting, with natural hair regrowth possible once the underlying issues are resolved. Patients experiencing noticeable hair loss are encouraged to evaluate for nutritional deficiencies, thyroid disorders, and other potential causes, rather than attributing the issue solely to their medication.

Patients should undergo comprehensive blood tests to assess levels of protein, iron, vitamin D, vitamin B12, zinc, and thyroid function to identify any deficiencies that might exacerbate hair shedding. Maintaining a balanced diet, rich in protein and necessary micronutrients, is recommended during weight loss journeys.

Despite the newly identified risks, health professionals advise against discontinuing GLP-1 medications without consulting a physician. These medications are regarded as effective for improving blood sugar control, facilitating sustained weight loss, and reducing obesity-related health issues. Dr. Santhanam highlighted the importance of not making treatment decisions based solely on aesthetic concerns about hair loss and encouraged seeking medical advice for any noticeable changes in hair condition.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share